Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

332 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    An Analysis Of Drug Trademark Genericide And Protection Of Brands From Dilution

    Aspirin, formerly known as a brand of painkiller manufactured by Bayer, now generally refers to any painkiller (but is still a registered trademark in Germany).
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    2016 Compliance Enforcement In The Pharmaceutical Industry

    Last year ushered in an abundance of new laws and regulations for the pharmaceutical industry in China. Various pharmaceutical policies, including national laws and regulations as well as local supporting policies such as the dual-invoice system, . . .
    ChinaFood, Drugs, Healthcare, Life Sciences
    JunHe Law Office
    JunHe Law Office
Article

China Issues Its First Guidelines On Celebrity Endorsements

The legal environment and potential liabilities for celebrity endorsements in China are getting tougher. Five months after Chinese actress Jing Tian was fined RMB 7.22 million for her illegal...
ChinaMedia, Telecoms, IT, Entertainment
Global Advertising Lawyers Alliance (GALA)
Global Advertising Lawyers Alliance (GALA)
  • Article

    BIOSECURE Act: Anticipated Movement, Key Provisions, And Likely Impact

    Last night, the House of Representatives passed the BIOSECURE Act (BIOSECURE or the Act) by a bipartisan vote of 306 to 81.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    脑机接口设备作为医疗器械监管及应用的常见法律问题

    人工智能和脑科学的交叉融合发展为机器智能与人类智能的融合提供了可能,在全球瞩目下,脑机接口技术在医疗场景的应用处在变革前夕,
    ChinaFood, Drugs, Healthcare, Life Sciences
    AnJie Broad Law Firm
    AnJie Broad Law Firm
  • Article

    解读人类遗传资源管理最新问答:人源细胞系、肿瘤异种移植模型(CDX/PDX)、CAR-T治疗材料监管问题

    近日,中国人类遗传资源主管部门国家卫生健康委员会下属的科技教育司发布了三则关于人类遗传资源管理的重要问题解答("《问题解答》")..
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    China's SAMR Fines Hunan Er-Kang And Henan Jiushi CNY 10 Million For Unfair Pricing Of Chlorpheniramine API

    On 30 December 2018, China's State Administration for Market Regulation (SAMR) issued an infringement decision imposing a total fine of CNY 10.04 million
    ChinaAntitrust/Competition Law
    Mayer Brown
    Mayer Brown
  • Article

    61款创新医疗器械获批:2023年度中国医疗器械注册工作报告亮点解读

    在前一篇文章《60余款创新药获批:2022-2023年度中国药品审评报告亮点解读》中,我们对2022-2023年度药品审评报告中所体现的我国近两年药品注册与监管
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    China's New State Market Regulatory Administration: What To Know And What To Expect

    On March 17, China's highest legislative body, the National People's Congress, approved a sweeping government restructuring plan.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    汉坤 • 观点 | 医药BD项目如何友好"分手"?

    医药BD(business development,商务拓展)项目通常指通过授权许可、投资、并购、合作开发/商业化等方式进行产品和技术的商业机会拓展。全球新冠疫情已逾三年,
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Understanding The EU's International Procurement Instrument

    Earlier this year, the Commission relied for the first time on the EU's International Procurement Instrument in order to take measures against China for its failure to ensure reciprocal access to public...
    ChinaGovernment, Public Sector
    Crowell & Moring LLP
    Crowell & Moring LLP
  • Article

    《私募股权投资基金大看台》系列文章之六

    在上一篇《私募股权投资基金大看台》系列文章中,我们对法律尽职调查做了概要性介绍。本文将在其基础上,对医药大健康领域的尽职调查$
    ChinaIntellectual Property
    AnJie Broad Law Firm
    AnJie Broad Law Firm
  • Article

    Continental Drift: SIPO's April 2017 Examination Guidelines Bring Significantly Improved Alignment With EU And US Rules In Software And Pharma Fields

    The Chinese State Intellectual Property Office has significantly revised its examination guidelines with respect to inventions relating to business methods and software, submission of post-filing data...
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    Draft Implementing Rules Of China's Human Genetic Resources Regulations As Applied To Foreign Persons

    The Administrative Regulations of the People's Republic of China on Human Genetic Resources (the "Regulations"), promulgated by China's State Council, have been in effect for almost three years.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Overview Of China Drug Review Annual Report (2015-2021)

    Since 2013, the National Medical Products Administration ("NMPA") Center for Drug Evaluation ("CDE") has been releasing a Drug Review Annual Report ("Report") each year, which summarizes...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

    In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.
    ChinaIntellectual Property
    Rouse
    Rouse
  • Article

    【判例】特許行政訴訟における新証拠の審理について

    最高人民法院知的財産権法廷が上訴人の四川新緑色薬業科技発展有限公司(以下、「新緑色薬業公司」という)と被上訴人の国家知識産権
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    Industry Observation|China Life Sciences And Healthcare Weekly Report No. 30

    为进一步完善全链条支持创新药发展举措,推动创新药高质量发展,更好满足人民群众多元化就医用药需求,国家医保局、国家卫生健康委联
    ChinaFood, Drugs, Healthcare, Life Sciences
    SGLA Law Firm
    SGLA Law Firm
  • Article

    China's Recent Development On Granting Biological Sequence Claims

    Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades.
    ChinaIntellectual Property
    Lung Tin
    Lung Tin
  • Article

    China On The Move: China's Healthcare And Life Sciences Regulatory Evolution In 2025

    In the first half of 2025, China's healthcare and life sciences regulatory framework underwent a wave of important reforms. These developments reflect the country's continued efforts toward global alignment...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Greenberg Traurig
    Greenberg Traurig
  • Showing 181–200 of 332 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics